The ensuing decrease in EZH2 expression, a component of the Polycomb Repressive complex 2 (PRC2) histone modifying complex, favors the development of MDS [82], initiation of MPN and development of MF, as observed in the case of EZH2 mutations [83]. Here, EZH2 is linked to myeloproliferative neoplasm.